SPOTLIGHT -
Annual Stimulant Prescriptions Have Doubled In Adolescents Since 2008
A retrospective analysis of controlled drug dispensation shows conflicting rates of prescriptions to teenagers and young adults.
Read More
FDA Approves Furosemide Injection for At-Home Treatment of Congestion in Chronic Heart Failure
The approval indicates the subcutaneous loop diuretic for the at-home treatment of congestion in adults with NYHA Class II/III chronic heart failure.
Consistent Published Evidence Lacking Behind FDA Regulatory Decisions Over FAERS Safety Signals
New data suggest transparency regarding drug safety regulatory response has not been consistent in recent years.
Cigarette Smoking, Insomnia and Depression Linked by CSF Metal Ion Levels
A new analysis suggests raise levels of zinc, iron, lead and aluminum—linked to cigarette use—is positively correlated with insomnia.
Fighting the Historic Disparities of Women's Heart Disease with Martha Gulati, MD
Martha Gulati, MD, joins The Heart Team to share her professional experiences and recommendations in treating female-specific cardiovascular disease.
Heart Team: Making Ground on Women's Cardiovascular Health
Martha Gulati, MD, joins episode 2 to discuss the burden of gender disparity in cardiovascular research, screening and care.
AI Algorithm May Help Identify Eligibility for Diabetic Retinopathy Clinical Trials
New data from AAO 2022 show how technology may refine a currently inefficient enrollment practice for retina disease assessment.
Bevacizumab Linked to Greater ROP Retreatment than Ranibizumab
A real-world comparison of the anti-VEGF agents suggests certain doses are associated with more likelihood of retreatment.
Proposed Aflibercept Biosimilar Provides Comparable Efficacy, Safety for DME
Findings from the INSIGHT study suggest MYL-1701P may provide a new anti-VEGF biosimilar option to patients with the common form of vision loss.
Initially Costlier, Ranibizumab PDS May Be More Cost-Effective Long-Term for nAMD Patients
New AAO 2022 data show the novel treatment administration may eventually save patients money versus standard anti-VEGF injfections.
EYP-1901 Safe, Tolerable for nAMD at 6 Months
New findings show the investigative single-dose agent is safe and associated with reduced rescue-dose anti-VEGF treatment.
Anti-VEGF Treatments Do Not Differ in Long-Term Intraocular Pressure
Comparison of 12- and 24-month regimens of common nAMD treatment show little difference in the common adverse event in patient eyes.
How AI, Machine Learning Are Providing an Edge on Interstitial Lung Disease
Simon Walsh, MD, and Elizabeth Estes join Lungcast to discuss advancements in biomarker and treatment option deliberation for the rare disease through data.
Paola Facheris, PhD: Distinctions in Adult-Onset and Pediatric Atopic Dermatitis
New EADV data suggest clinicians may need to uniquely treat patients with adult-onset eczema based on inflammatory pathways.
FDA Approves Aprepitant IV Injection for Post-Surgery Vomiting, Nausea Prevention
The approval is based on data from 2 clinical trials showing the agent improved the rate of post-operation patients avoiding sickness by 50%.
Emma Guttman, MD, PhD: Rocatinlimab for Atopic, Head and Neck Dermatitis
The novel OX40 inhibitor molecule showed significant benefit for patients in new EADV 2022 data. A lead author discusses its potential.
FDA Approves Deucravacitinib for Adults with Plaque Psoriasis
The daily TYK2 inhibitor agent was associated with improved rates of psoriasis surface improvement versus apremilast in clinical trials.
Emma Guttman, MD, PhD: Abrocitinib Impacts Atopic Dermatitis Biomarkers
The Icahn investigator discusses her team's new EADV 2022 data on the JAK inhibitor.
Cardiology & Nephrology Collaborations with Dr. Matthew Weir
In this podcast episode, Jorge Plutzky, MD, and Michael Farkouh, MD, speak with University of Maryland's Matthew Weir, MD, about the growing involvement of renal care in modern heart disease patients.
Heart Team: The Evolving Role of Kidney Disease in CVD
In the first episode of our monthly series, cardiologists Jorge Plutzky, MD, and Michael Farkouh, MD, interview nephrologist Matthew Weir, MD.
2021 Lung Cancer Screening Guideline Update Benefitted Black Adult Eligibility
New cohort analysis suggest updates to broaden the age and smoking-rate eligibility may have benefitted the historic disparity in low-dose CT screening practice.
Primary Care Telehealth Device Use Varies by Age, Race, Income
A cross-sectional analysis of a Penn Medicine primary care practice shows which patients may prefer a phone or tablet versus a computer.
Addressing Older Homeless Adult Health Concerns
Rebecca T. Brown, MD, MPH, discusses the growing prevalence of older homeless adults, and what diseases community leaders and caregivers are combating most frequently in them.
Long-Term Opioid Tapering Does Not Benefit Suicide, Overdose Risks
New comparative effectiveness data go against CDC recommendations for tapering or abruptly ending long-term opioid prescription.
FDA Approves Baloxavir Marboxil to Treat, Prevent Flu in Younger At-Risk Children
The newest indications for the novel oral antiviral drug will make it available as an acute treatment and prophylaxis for children this flu season.
Up in Smoke: The FDA's Retroactive Fight to Limit E-Cigarettes
The agency has taken new action against Juul while experts worry about youth addiction and health impacts. But the e-cigarette market has been already well established in the US.
Ensifentrine Significantly Improves COPD Lung Function, Exacerbations
New phase 3 ENHANCE-2 data support a potential submission by Verona Pharma to the FDA.
Obstructive Sleep Apnea: Common Symptoms and Misconceptions
Reena Mehra, MD, MS, reviews telling signs, the role of obesity, and the importance of proper testing for sleep apnea.
Mark Lebwohl, MD: Optimizing Roflumilast Cream in Dermatology
The pivotal DERMIS trial author discusses extended assessment and prescribing strategies for the latest psoriasis agent.
Asian Patients with Psoriasis Receive Significantly Less Time with Dermatologists
A retrospective analysis suggests there are significant disparities in dermatologist visit duration based on patient race and ethnicity.
